BHBryan Har

Bryan Har

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bryan Har has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Derivation and Validation of Risk Prediction Models for Cardiovascular and Kidney Outcomes of Non‐ST‐Segment–Elevation Acute Coronary Syndrome in Patients With Chronic Kidney Disease

    by Todd A. Wilson, Lee Er, Tolulope T. Sajobi, Stephen B. Wilton, Glen S. Hazlewood, Peter Birks, Adeera Levin, Michelle M. Graham, Bryan Har, Matthew T. James

    Background: Patients with chronic kidney disease are at high risk of adverse outcomes after acute coronary syndrome (ACS) and need optimized treatment decisions. We derived and validated a series of risk models for predicting 1‐year mortality, readmission for myocardial infarction, and progression to kidney failure following ACS. Methods: The development cohort included adults with chronic kidney disease who had an admission for non‐ST‐segment–elevation ACS, in Alberta, Canada between April 1, 2004 and March 31, 2017. Cox proportional hazard and Fine and Gray competing risk models were externally validated and updated in a temporally distinct cohort of patients in Alberta and a geographically distinct cohort of patients with chronic kidney disease and ACS in British Columbia, Canada. Results: The derivation cohort included 11 980 patients, the temporal validation cohort 4204, and the geographic validation cohort 1787. All models showed comparable discrimination and calibration in the temporal validation cohort; comparable model performance was achieved in the geographic validation cohort after updating. In the temporal and geographic validation cohorts, respectively, discrimination was very good for kidney failure (C‐indexes, 0.93 [95% CI, 0.89–0.97] and 0.80 [95% CI, 0.78–0.82]), and modest for mortality (0.77 [95% CI, 0.75–0.78] and 0.71 [95% CI, 0.69–0.73]), and readmission for myocardial infarction (0.65 [95% CI, 0.62–0.67] and 0.57 [95% CI, 0.53–0.62]). All models were well calibrated after updating. Conclusions: We have developed, validated, and updated risk models for cardiac and renal outcomes in patients with chronic kidney disease and ACS, which can help facilitate shared decision‐making surrounding diagnostic testing, treatment, and monitoring of these patients.

  • Open Access

    My Heart and CKD: Pathway to Implementing a Decision Aid for Patients With CKD and Coronary Artery Disease

    by Julie N. Babione, Pantea Javaheri, Denise Kruger, Todd Wilson, Winnie Pearson, Maureena Loth, Violet March, Wayne Gerber, Bryan J. Har, Michelle M. Graham, et al.

    Background: Patients with chronic kidney disease (CKD) at times must decide whether to take an invasive approach to management of coronary artery disease (CAD), which involves procedures such as angiography, angioplasty, and surgery, versus attempt management with medications alone. My Heart and CKD is a decision aid to support shared decision-making (SDM) between patients and their care providers in these situations. This report describes the pathway to implement My Heart and CKD , and key learnings that have emerged through this process. Methods: Human-centered design was used to develop the decision aid while concurrently identifying design features that could facilitate its incorporation within patient-physician clinical encounters. Interviews exploring use of the decision aid with patients and care providers were qualitatively analyzed according to the theoretical domains framework to identify barriers and facilitators to implementation. Simulated encounters between patient and physicians were used for pre-clinical testing and to identify additional training and resources that could support effective implementation. Key Findings: Implementation insights overlapped with decision-aid design input and influenced key design elements of My Heart and CKD as well as the development of implementation strategies to facilitate its clinical use. An overarching theme that influenced development and implementation was the concept that the decision aid be designed for use by patients and physicians together, to support the bidirectional communication and relationship building intended with SDM. This influenced design features to support varying use preferences and contexts, encompassing both digital and paper-based forms for use. Implementation considerations also influenced order and arrangement of content in My Heart and CKD to enhance integration of all stages of SDM into varying clinical environments. Additional training and implementation resources, including an accredited continuous medical education program for care providers, were identified as additional facilitators necessary to support implementation. Limitations: Clinical evaluation has not yet been completed. Implications: My Heart and CKD is intended to support personalized, patient-centered care by providing patients with CKD and CAD and their care providers with tools to engage in SDM. Further research will evaluate the effectiveness of its implementation and impact on the quality of decision-making.

  • Open Access

    Perceived Potential and Challenges of Supporting Coronary Artery Disease Treatment Decisions With AI: Qualitative Study

    by Khara Sauro, Bishnu Bajgain, Cody van Rassel, Bryan Har, Robert Welsh, Joon Lee

    Background: Coronary revascularization decision-making for patients with coronary artery disease (CAD) can be complex and challenging. Artificial intelligence (AI) has the potential to improve this decision-making by bringing data-driven insights to the point of care. Objective: We aimed to elicit, collect, and analyze various stakeholders’ perceived potential and challenges related to developing, implementing, and adopting AI-based CAD treatment decision support systems. Methods: A facilitated small-group discussion method, known as a World Café, was conducted with general cardiologists, interventional cardiologists, cardiac surgeons, patients, caregivers, health system administrators, and industry representatives. One-on-one interviews were conducted for participants who could not attend the World Café. Perceived potential and challenges of AI-based CAD treatment decision support systems were solicited by asking participants three broad questions: (1) What is most challenging about revascularization decision-making? (2) How could an AI tool be integrated into the existing clinical workflow? (3) What are the critical components that need to be considered when developing the AI tool? Thematic analysis was performed to identify themes from the data. Results: Nine participants completed the World Café, and 3 participants completed the one-on-one interviews. Five main themes emerged: (1) evidence-based care, (2) workload and resources, (3) data requirements (subthemes: patient-centered approach, evidence-based AI, and data integration), (4) tool characteristics (subthemes: end user built; generation and presentation of decision support information; user-friendliness and accessibility; and system logic, reasoning, and data privacy), and (5) incorporation into clinical workflow (subthemes: AI as an opportunity to improve care and knowledge translation). Conclusions: While health care providers aim to provide evidence-based care, CAD treatment decision-making can often be subjective due to the limited applicability of clinical practice guidelines and randomized controlled trial evidence to individual patients. AI-based clinical decision support systems may be an effective solution if the development and implementation focus on the issues identified by end users in this study (patient preference, data privacy, integration with clinical information systems, transparency, and usability).

  • Open Access

    Developing a Computational Phenotype of the Fourth Universal Definition of Myocardial Infarction for Inpatients

    by Elliot A. Martin, Bryan Har, Robin L. Walker, Danielle A. Southern, Hude Quan, Cathy A. Eastwood

    Background: The fourth universal definition of myocardial infarction (MI) introduced the differentiation of acute myocardial injury from MI. In this study, we developed a computational phenotype for distinct identification of acute myocardial injury and MI within electronic medical records (EMRs). Methods: Two cohorts were used from a Calgary-wide EMR system: a chart review of 3042 randomly selected inpatients from Dec 2014 to Jun 2015; and 11,685 episodes of care that included cardiac catheterization from Jan 2013 to Apr 2017. Electrocardiogram (ECG) reports were processed using natural language processing and combined with high-sensitivity troponin lab results to classify patients as having an acute myocardial injury, MI, or neither. Results: For patients with an MI diagnosis, only 64.0% (65.7%) in the catheterized cohorts (chart review cohort) had two troponin measurements within 6 h of each other. For patients with two troponin measurements within 6 h; of those with an MI diagnosis, our phenotype classified 25.2% (31.3%) with an acute myocardial injury and 62.2% (55.2%) with an MI in the catheterized cohort (chart review cohort); and of those without an MI diagnosis, our phenotype classified 12.9% (12.4%) with an acute myocardial injury and 10.0% (13.1%) with an MI in the catheterized cohort (chart review cohort). Conclusions: Patients with two troponin measurements within 6 h, identified by our phenotype as having either an acute myocardial injury or MI, will at least meet the diagnostic criteria for an acute myocardial injury (barring lab errors) and indicate many previously uncaptured cases. Myocardial infarctions are harder to be certain of because ECG report findings might be superseded by evidence not included in our phenotype, or due to errors with the natural language processing.


  • Open Access

    Hospital and Physician Variability in Revascularization Decisions and Outcomes for Patients With 3‐Vessel and Left Main Coronary Artery Disease: A Population‐Based Cohort Study

    by Todd Wilson, Matthew T. James, Danielle Southern, Bryan Har, Michelle M. Graham, Neil Brass, Kevin Bainey, Paul W. M. Fedak, Tolulope T. Sajobi, Stephen B. Wilton

    Background: Hospital‐ and physician‐level variation for selection of percutaneous coronary intervention versus coronary artery bypass grafting (CABG) for patients with coronary artery disease has been associated with outcome differences. However, most studies excluded patients treated medically. Methods and Results: From 2010 to 2019, adults with 3‐vessel or left main coronary artery disease at 3 hospitals (A, B, C) in Alberta, Canada, were categorized by treatment with medical therapy, percutaneous coronary intervention, or CABG. Multilevel regression models determined the proportion of variation in treatment attributable to patient, physician, and hospital factors, and survival models assessed outcomes including death and major adverse cardiovascular events over 5 years. Of 22 580 patients (mean age, 67 years; 80% men): 6677 (29%) received medical management, 9171 (41%) percutaneous coronary intervention, and 6732 (30%) CABG. Hospital factors accounted for 10.8% of treatment variation. In adjusted models (site A as reference), patients at sites B and C had 49% (95% CI, 44%–53%) and 43% (95% CI, 37%–49%) lower rates of medical therapy, respectively, and 31% (95% CI, 24%–38%) and 32% (95% CI, 24%–40%) lower rates of CABG. During 5.0 years median follow‐up, 3287 (14.6%) patients died, with no intersite mortality differences. There were no between‐site differences in acute coronary syndromes or stroke; patients at sites B and C had 24% lower risk (95% CI, 13%–34% and 11%–35%, respectively) of heart failure hospitalization. Conclusions: Hospital‐level variation in selection of percutaneous coronary intervention, CABG, or medical therapy for patients with complex coronary artery disease was not associated with differences in 5‐year mortality rates. Research and quality improvement initiatives comparing revascularization practices should include medically managed patients.


  • Open Access

    Correction to: Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i

    by Erin S. Mackinnon, Bryan Har, Salimah Champsi, Rajvi J. Wani, Lee Geyer, Eileen Shaw, Megan S. Farris, Todd J. Anderson

  • Open Access

    Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i

    by Erin S. Mackinnon, Bryan Har, Salimah Champsi, Rajvi J. Wani, Lee Geyer, Eileen Shaw, Megan S. Farris, Todd J. Anderson

    Introduction A high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI. Methods A retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date. Results The cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively. Conclusions Intensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes.


  • Open Access

    Change Management Accompanying Implementation of Decision Support for Prevention of Acute Kidney Injury in Cardiac Catheterization Units: Program Report

    by Bryan Ma, Matthew T. James, Pantea A. Javaheri, Denise Kruger, Michelle M. Graham, Bryan J. Har, Benjamin D. Tyrrell, Shane Heavener, Clare Puzey, Eleanor Benterud

    Purpose of program: Different models exist to guide successful implementation of electronic health tools into clinical practice. The Contrast Reducing Injury Sustained by Kidneys (Contrast RISK) initiative introduced an electronic decision support tool with physician audit and feedback into all of the cardiac catheterization facilities in Alberta, Canada, with the goal of preventing contrast-associated acute kidney injury (CA-AKI) following coronary angiography and intervention. This report describes the change management approaches used by the initiative and end-user’s feedback on these processes. Sources of information and methods: The Canada Health Infoway Change Management model was used to address 6 activities relevant to project implementation: governance and leadership, stakeholder engagement, communications, workflow analysis and integration, training and education, and monitoring and evaluation. Health care providers and invasive cardiologists from all sites completed preimplementation, usability, and postimplementation surveys to assess integration and change success. Key findings: Prior to implementation, 67% of health providers were less than satisfied with processes to determine appropriate contrast dye volumes, 47% were less than satisfied with processes for administering adequate intravenous fluids, and 68% were less than satisfied with processes to ensure follow-up of high-risk patients. 48% of invasive cardiologists were less than satisfied with preprocedural identification of patients at risk of acute kidney injury (AKI). Following implementation, there were significant increases among health providers in the odds of satisfaction with processes for identifying those at high risk of AKI (odds ratio [OR] 3.01, 95% confidence interval [CI] 1.36-6.66, P = .007), quantifying the appropriate level of contrast dye for each patient (OR 6.98, 95% CI 3.06-15.91, P < .001), determining the optimal amount of IV fluid for each patient (OR 1.86, 95% CI 0.88-3.91, P = .102), and following up of kidney function of high risk patients (OR 5.49, 95%CI 2.45-12.30, P < .001). There were also significant increases among physicians in the odds of satisfaction with processes for identifying those at high risk of AKI (OR 19.53, 95% CI 3.21-118.76, P = .001), quantifying the appropriate level of contrast dye for each patient (OR 26.35, 95% CI 4.28-162.27, P < .001), and for following-up kidney function of high-risk patients (OR 7.72, 95% CI 1.62-36.84.30, P = .010). Eighty-nine percent of staff perceived the initiative as being successful in changing clinical practices to reduce the risk of CA-AKI. Physicians uniformly agreed that the system was well-integrated into existing workflows, while 42% of health providers also agreed. Implications: The Canada Health Infoway Change Management model was an effective framework for guiding implementation of an electronic decision support tool and audit and feedback intervention to improve processes for AKI prevention within cardiac catheterization units.